Table 2.

Epidemiologic profile and neurologic manifestations

	Population of COVID-19 patients with extensive white matter microhemorrhages (n = 19)	Population of COVID-19 patients without extensive white matter microhemorrhages (n = 18)	p value
Sex
Male/female	16 (84%)/3 (16%)	13 (72%)/5 (28%)	0.44
Age (years)
Range/median (Q1–Q3)	44–79/66 (60–70)	21–72/62 (55–68)	0.17
History of stroke	3 (16%)	1 (6%)	0.6
Cardiovascular risk factors
High blood pressure	7 (37%)	10 (56%)	0.33
Type 2 diabetes mellitus	2 (11%)	6 (33%)	0.12
Hyperlipidemia	7 (37%)	7 (39%)	1
Smoking	4 (21%)	2 (11%)	0.65
Weight (kg)	90 (78–95)	89 (80–97)	0.87
Body mass index	29 (26–32)	28 (26–33)	1
Intensive care unit stay
Duration (days)	34 (29–45)	17 (11–21)	0.0004
Time between intubation and brain MRI (days)	26 (20–31)	12 (6–18)	0.0003
Hospital length of stay (days)	44 (40–54)	32 (22–37)	0.007
Hospital discharge	7 (37%)	13 (72%)	0.04
Death of the patient	4 (21%)	1 (6%)	0.33
Neurologic manifestations leading to the realization of the brain MRI
Seizures	4 (21%)	0	0.1
Clinical signs of corticospinal tract involvement	3 (16%)	4 (22%)	0.69
Disturbance of consciousness	13 (68%)	2 (11%)	0.0006
Confusion	5 (26%)	12 (67%)	0.02
Agitation	4 (21%)	10 (56%)	0.04
Pathological wakefulness when sedative therapies were stopped	17 (89%)	14 (78%)	0.4

Data are number and percentage or median associated with first and third quartile

All statistical test results are in italics. Statistically significant results are in bold italics